Track topics on Twitter Track topics that are important to you
Long-term Immunogenicity Of A Live Herpes Zoster Vaccine In Systemic Lupus Erythematosus (SLE) Patients PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Long-term Immunogenicity Of A Live Herpes Zoster Vaccine In Systemic Lupus Erythematosus (SLE) Patients articles that have been published worldwide.
We have published hundreds of Long-term Immunogenicity Of A Live Herpes Zoster Vaccine In Systemic Lupus Erythematosus (SLE) Patients news stories on BioPortfolio along with dozens of Long-term Immunogenicity Of A Live Herpes Zoster Vaccine In Systemic Lupus Erythematosus (SLE) Patients Clinical Trials and PubMed Articles about Long-term Immunogenicity Of A Live Herpes Zoster Vaccine In Systemic Lupus Erythematosus (SLE) Patients for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Long-term Immunogenicity Of A Live Herpes Zoster Vaccine In Systemic Lupus Erythematosus (SLE) Patients Companies in our database. You can also find out about relevant Long-term Immunogenicity Of A Live Herpes Zoster Vaccine In Systemic Lupus Erythematosus (SLE) Patients Drugs and Medications on this site too.
Clinical observations from the international literature report that herpes zoster occurs after varicella vaccination in immunocompetent children. We present the case of a four-year-old immunocompetent girl who developed herpes zoster after she had received one dose of varicella-zoster virus live attenuated vaccine at the age of 15 months. Continued surveillance for herpes zoster among vaccinated persons is important to evaluate the varicella vaccination program and to detect any changes in the epidemiology ...
Herpes zoster (HZ) is caused by varicella-zoster virus ( VZV ) reactivation. In the United States, Zoster vaccine (ZOSTAVAX) is indicated for HZ prevention in patients ≥50 years.
The recombinant adjuvanted zoster vaccine (RZV, trade name Shingrix) is preferentially recommended by the Advisory Committee on Immunization Practices to prevent herpes zoster and related complications in immunocompetent adults age 50 years and older. This article reviews efficacy and safety of the vaccine, its use in special populations, and how to prevent administration errors to answer the question "Which patients should receive the herpes zoster vaccine?"
Zoster vaccine live (ZVL [Zostavax]) has been recommended for the prevention of herpes zoster (HZ) among immunocompetent adults ≥60 years in the United States since 2008. To examine changes in healthcare providers' perceptions and practices related to HZ disease and vaccination, we administered surveys to national networks of primary care physicians in 2005, 2008, and 2016. Ten years after ZVL was first licensed, physicians were more likely to respond that they perceived HZ as a serious disease and more...
Herpes zoster, a frequent complication following autologous hematopoietic stem cell transplantation (HSCT), is associated with significant morbidity. A nonlive adjuvanted recombinant zoster vaccine has been developed to prevent posttransplantation zoster.
To explore herpes zoster (HZ) rates, and live zoster vaccine (LZV) safety, in a subset of patients with rheumatoid arthritis (RA) who received LZV before tofacitinib ± methotrexate (MTX), or adalimumab (ADA) + MTX, in ORAL Strategy.
The adjuvanted recombinant glycoprotein E herpes zoster (HZ) vaccine is superior to the live attenuated HZ vaccine, with an efficacy >90% against HZ in healthy immunocompetent adults aged ≥50 years after vaccination. In pivotal studies, the efficacy of the new vaccine varied very little with the age of the vaccinee and decreased only by 5-10% in the 3.5 years after immunization. This nonlive vaccine was successfully administered to small cohorts of immunocompromised individuals; initial trials showed effi...
Chickenpox is a highly contagious vaccine-preventable disease that can lead to severe complications, especially in immunocompromised patients. Varicella-zoster virus (VZV) vaccine appears to be safe and immunogenic in pediatric solid organ transplant recipients, but there are few data on the long-term vaccine-induced seroprotection.
Herpes zoster (HZ) is caused by reactivation of varicella zoster virus (VZV) that established latency in sensory and autonomic neurons during primary infection. In the Shingles Prevention Study (SPS), a large efficacy trial of live attenuated Oka/Merck zoster vaccine (ZVL), PCR-confirmed second episodes of HZ occurred in two of 660 placebo and one of 321 ZVL recipients with documented HZ during a mean follow-up of 3.13 years. An additional two ZVL recipients experienced a second episode of HZ in the Long-...
Herpes zoster (HZ), also known as shingles, results from reactivation of the latent varicella-zoster virus (VZV), which commonly causes chickenpox in childhood. Greater than 90% of adults are infected with this virus, putting them at risk for reactivation. HZ presents as a painful, vesicular rash distributed in a unilateral and dermatomal pattern along dorsal root or cranial nerve ganglia. The rash often presents with prodromal symptoms and progresses to include clear vesicular clusters, evolving through st...
In South Korea, the population is rapidly aging and the prevalence of comorbidities has increased. We investigated longitudinal changes in the herpes zoster (HZ) considering demographic changes and comorbidities in the era of universal single-dose varicella vaccination.
This study aimed to investigate the risk of sudden sensorineural hearing loss (SSNHL) in Herpes zoster patients from a representative population cohort. A longitudinal follow-up study Data were obtained from the Korean National Health Insurance Service-National Sample Cohort for the period from 2002 to 2013. We matched 61,702 subjects in the Herpes zoster group with subjects in a control group (246,808 subjects with no history of Herpes zoster) based on demographic factors (age, sex, income, and region of...
Immunocompromised subjects are at increased risk for herpes zoster (HZ) and HZ-related complications, such as post herpetic neuralgia (PHN). We describe health utilities, health care resource utilization (HCRU), productivity loss and health care costs in recipients of autologous hematopoietic stem cell transplantation (Auto-HSCT) who developed confirmed HZ in the phase 3 clinical trial.
The features of herpes zoster share some commonalities with depression, including decreased cellular immunity, a close correlation with nutritional status, and a higher prevalence in the elderly population. We aimed to assess the association between herpes zoster infection and depression in the Korean population.We performed a longitudinal follow-up study of a nationwide sample cohort derived from the Korean National Health Insurance Service database. Individuals diagnosed with depression between 2002 and 2...
To study clinical characteristics of Herpes zoster in infants.
Clinical differentiation between herpes zoster and superficial skin and soft tissue infections of the face can be difficult. In addition, diagnosis can be complicated by bacterial superinfection of lesional herpes zoster. The aim of this study was to determine whether inflammatory parameters, such as C-reactive protein (CRP) and blood counts, might be reliable biomarkers to distinguish between skin and soft tissue infections and herpes zoster when the face is infected. The study data (multivariate analysis ...
Herpes zoster (HZ) may cause complications; however, the information regarding complications of HZ in children is relatively sparse. We retrospectively reviewed cases of HZ in children and investigated the risk factors contributing to the development of complications.
Data on the epidemiology of herpes zoster (HZ), particularly in the unvaccinated, immunocompetent population, are needed to assess disease burden and the potential impact of vaccination.
Schistosomes infect approximately 250 million people worldwide. To date, there is no effective vaccine available for the prevention of schistosome infection in endemic regions. There remains a need to develop means to confer long-term protection of individuals against reinfection. In this study, an annexin, namely annexin B30, which is highly expressed in the tegument of Schistosoma mansoni was selected to evaluate its immunogenicity and protective efficacy in a mouse model.
Levels of antibodies induced by the Measles virus containing vaccine have been shown to decline over time, but actually there is not a formal recommendation about the opportunity of testing immunized subjects (in particular, HCWs) to investigate the persistence of Measles IgG.
A human model to better understand tuberculosis immunopathogenesis and facilitate vaccine development is urgently needed. We evaluated the feasibility, safety, and immunogenicity of live Bacille-Calmette-Guerin (BCG) in a lung-orientated controlled human infection model.
The objective of this review was to evaluate the role of diabetes as a risk factor for herpes zoster (HZ) and to discuss implications of prevention by vaccination with available HZ vaccines.
Patients with chronic inflammatory skin diseases (CISD) have potential risk factors for herpes zoster (HZ). Yet, little is known about HZ risk in CISD.
Subjects receiving the same vaccine often show different levels of immune responses and some may even present adverse side effects to the vaccine. Systems vaccinology can combine omics data and machine learning techniques to obtain highly predictive signatures of vaccine immunogenicity and reactogenicity. Currently, several machine learning methods are already available to researchers with no background in bioinformatics. Here we described the four main steps to discover markers of vaccine immunogenicity an...